TP53 and hematopoietic and lymphoid cell neoplasm: The inhibitor was able to reduce the viability of multiple TP53 wild-type cell lines, including several hematologic cancers, and MYCN amplified NB cell lines, as well as a subset of TP53 mutant cell lines [186].